Calprotectin Levels in Necrotizing Enterocolitis

Necrotizing enterocolitis (NEC) is a serious condition that can affect premature babies, leading to complications like intestinal damage and infection. In our study, we measured specific markers (called calprotectin) in blood and stool to understand how severe NEC is and predict outcomes. We found that these markers were higher in babies with more severe NEC (stage 3), especially in those who needed surgery or sadly did not survive. This information can help doctors detect NEC earlier, understand its severity, and make better decisions for treating affected babies.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Necrotising Enterocolitis Neonatal Digestive System Diseases Enterocolitis Enterocolitis, Necrotizing Gastroenteritis Gastrointestinal Diseases Intestinal Diseases

Age range

3 day–30 day

Sex eligibility

All sexes

Study type

Observational

Primary location

Ankara Bilkent City Hospital

Ankara, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

before 32 weeks of gestation with a birth weight of ≤1500 grams

Exclusion criteria

Infants whose families did not provide consent and those with congenital anomalies were excluded.

Treatment and study plan

Primary outcomes

The predictive value of serum and fecal calprotectin levels in necrotising enterocolitis (NEC)

Time frame: 2 years

The predictive value of serum and fecal calprotectin levels in assessing NEC severity (stage 2 and stage 3), intestinal perforation, the need for surgery, and mortality.

Sponsors and collaborators

Lead sponsor

Ankara Yildirim Beyazıt University

Other

Registry information

Official study title

A Comparative Study of Serum and Fecal Calprotectin Levels in Necrotizing Enterocolitis

Important dates

Study start: 2022
Primary completion: 2024
Study completion: 2024
First posted: Nov 18, 2024
Registry last updated: Nov 18, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed